Camurus (CAMX) Stock Overview
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CAMX Community Fair Values
Create NarrativeSee what 53 others think this stock is worth. Follow their fair value or set your own to get alerts.
Camurus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 613.00 |
| 52 Week High | SEK 754.50 |
| 52 Week Low | SEK 483.80 |
| Beta | 0.44 |
| 1 Month Change | -4.74% |
| 3 Month Change | -11.67% |
| 1 Year Change | 8.88% |
| 3 Year Change | 131.85% |
| 5 Year Change | 229.22% |
| Change since IPO | 828.79% |
Recent News & Updates
Camurus AB (publ)'s (STO:CAMX) Intrinsic Value Is Potentially 69% Above Its Share Price
Dec 08
Analysts Have Just Cut Their Camurus AB (publ) (STO:CAMX) Revenue Estimates By 11%
Nov 19Recent updates
Camurus AB (publ)'s (STO:CAMX) Intrinsic Value Is Potentially 69% Above Its Share Price
Dec 08Analysts Have Just Cut Their Camurus AB (publ) (STO:CAMX) Revenue Estimates By 11%
Nov 19Here's What Analysts Are Forecasting For Camurus AB (publ) (STO:CAMX) Following Its Earnings Miss
Nov 09If EPS Growth Is Important To You, Camurus (STO:CAMX) Presents An Opportunity
Oct 19Should You Be Adding Camurus (STO:CAMX) To Your Watchlist Today?
Jun 10There May Be Underlying Issues With The Quality Of Camurus' (STO:CAMX) Earnings
May 23There's No Escaping Camurus AB (publ)'s (STO:CAMX) Muted Revenues Despite A 27% Share Price Rise
May 08Camurus AB (publ)'s (STO:CAMX) Popularity With Investors Is Under Threat From Overpricing
Mar 09
Buvidal And Brixadi Expansion To Fuel Revenue Growth And Boost Profit Margins
Strong R&D pipeline and successful regulatory progress signal future revenue growth from new treatments entering various markets.Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark
Dec 07Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality
Nov 15Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 10What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You
Aug 09Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts
Jul 19We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease
Jul 12Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders
May 02Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects
Apr 19Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality
Feb 22With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case
Feb 17Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected
Dec 20Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues
Nov 11Shareholder Returns
| CAMX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 2.6% | 1.5% | -0.02% |
| 1Y | 8.9% | -2.7% | 4.1% |
Return vs Industry: CAMX exceeded the Swedish Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: CAMX exceeded the Swedish Market which returned 4.1% over the past year.
Price Volatility
| CAMX volatility | |
|---|---|
| CAMX Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.5% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: CAMX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CAMX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 280 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.
Camurus AB (publ) Fundamentals Summary
| CAMX fundamental statistics | |
|---|---|
| Market cap | SEK 36.55b |
| Earnings (TTM) | SEK 781.67m |
| Revenue (TTM) | SEK 2.35b |
Is CAMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAMX income statement (TTM) | |
|---|---|
| Revenue | SEK 2.35b |
| Cost of Revenue | SEK 153.08m |
| Gross Profit | SEK 2.20b |
| Other Expenses | SEK 1.42b |
| Earnings | SEK 781.67m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 12, 2026
| Earnings per share (EPS) | 13.11 |
| Gross Margin | 93.50% |
| Net Profit Margin | 33.21% |
| Debt/Equity Ratio | 0% |
How did CAMX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 23:22 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Camurus AB (publ) is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Gonzalo Artiach Castanon | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |